Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|10 CitationsGLP-1 & MetabolicFemale-friendly

5-Amino-1MQ Dosing Protocol: NNMT Inhibitor Research

Also known as: 5-amino-1-methylquinolinium, NNMT Inhibitor

Dose Range
1.5 mgResearch range
0Typical research window: 1.5 mg2.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Metabolic Study): 1.5 mg/kg, Daily.

Protocol at a Glance
How Often
Daily

Daily

A Typical Run
10 days

Research-reported range; the linked study used a different dose or units.

How It's Taken
Vial / Oral

Oral

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 1.5 mg60 units

All U-100: 100 units = 1 mL. 3 doses in the vial at the low end.

Track the doses you run

Save 5-Amino-1MQ to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

5-Amino-1MQ supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-UUBCEN, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$90.00
50mg vial
$1.80/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$100.00
50mg vial
$2.00/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$120.00
50mg vial
$2.40/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$120.99
50mg vial
$2.42/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$74.97
10mg vial
$7.50/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Oral Small-Molecule Metabolic & Nuclear Receptor Modulator
Administration Route
Oral capsule or liquid solution (Non-injectable small molecule)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. 5-Amino-1MQ is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

5-Amino-1MQ is a small molecule that inhibits NNMT (Nicotinamide N-methyltransferase). Research has investigated its potential effects on metabolism and fat loss.

Mechanisms of Action

  • Inhibits NNMT enzyme
  • Increases NAD+ levels
  • Enhances metabolic rate
  • Promotes fat oxidation

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Metabolic Study
animal study
1.5 mg/kgDaily10 daysOralanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (5-Amino-1MQ)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

7 Human3 Animal

Mechanistically, NNMT overexpression in tubular epithelial cells exacerbates senescence and partial epithelial-to-mesenchymal transition, while selective NNMT inhibition in senescent kidney cells, organoids, and in vivo is protective. Altogether, these findings position NNMT as a promising therapeutic target to reduce tubular senescence and fibrosis in early CKD.

Limitations: No placebo control reported.

2026|Cell reports
PubMed

Using high-throughput screening, we develop a potent and specific NNMT inhibitor that reduces the tumour burden and metastasis in multiple mouse cancer models and restores immune checkpoint blockade efficacy by decreasing CAF-mediated recruitment of MDSCs and reinvigorating CD8+ T cell activation. Our findings establish NNMT as a central CAF regulator and a promising therapeutic target to mitigate immunosuppression in the tumour microenvironment.

Limitations: No placebo control reported.

2025|Nature
PubMed

This was accompanied by decreased pro-inflammatory and pro-fibrotic gene expression in plasma and LV tissue and reduced macrophage infiltration in LV and visceral adipose tissue, highlighting the anti-inflammatory and anti-fibrotic effects of NNMT inhibition. Targeting the NNMT is cardioprotective and holds promise for treating HFpEF patients with an unfavorable cardiometabolic phenotype.

Limitations: Animal study only — human translation uncertain.

2025|Pharmacological research
PubMed

5A1MQ treatment dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia in DIO mice. Liver histology from 5A1MQ-treated DIO mice showed attenuated hepatic steatosis and macrophage infiltration, and correspondingly reduced liver weight, size, and triglyceride levels.

Limitations: Animal study only — human translation uncertain.

2024|Diabetes, obesity &amp; metabolism
PubMed

Here, we identified that NNMT can promote IL6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression by decreasing the tri-methyl-histone H3 levels on the promoters of IL6 and CSF2 (encoding GM-CSF) and CCAAT/Enhancer Binding Protein, an essential transcription factor for IL6 expression, thus promoting differentiation of macrophages into M2 type tumor-associated macrophages and generation of myeloid-derived suppressor cells from peripheral blood mononuclear cells. Treatment of xenografted tumor models overexpressing NNMT gallbladder carcinoma (GBC) cells with the NNMT inhibitor JBSNF-000088 resulted in compromised tumor development and decreased expression levels of IL6, GM-CSF, tumor-associated macrophage marker CD206, and myeloid-derived suppressor cell marker CD33 but increased expression levels of CD8.

Limitations: No placebo control reported.

2023|Hepatology (Baltimore, Md.)
PubMed

Despite the increasing evidence indicating NNMT as a viable therapeutic target, the development of cell-active inhibitors against this enzyme is lacking. In this review, we provide an overview of the current status of NNMT inhibitor development, relevant in vitro and in vivo studies, and a discussion of the challenges faced in the development of NNMT inhibitors.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Drug discovery today
PubMed

Chronic alcohol consumption induces endoplasmic reticulum (ER) stress and upregulates NNMT expression in the liver. ER stress inducers upregulated NNMT expression in both AML12 hepatocytes and mice.

Limitations: Animal study only — human translation uncertain.

2021|Journal of hepatology
PubMed

NNMT is emerging as a key point of intersection between cellular metabolism and epigenetic gene regulation, and growing evidence supports its central role in several pathologies. The use of molecules that target NNMT represents a current pharmaceutical challenge for the treatment of several metabolic-related disease as well as in cancer.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Molecular metabolism
PubMed

These findings are further supported by isothermal titration calorimetry binding assays as well as modeling studies. The most active NNMT inhibitor identified in the present study demonstrated a dose-dependent inhibitory effect on the cell proliferation of the HSC-2 human oral cancer cell line.

Limitations: No placebo control reported.

2020|Journal of medicinal chemistry
PubMed

The structure of the NNMT-6 complex has unambiguously demonstrated that 6 occupied both substrate and cofactor binding sites. The findings paved the way for developing more potent and selective NNMT inhibitors in the future.

Limitations: No placebo control reported.

2019|Journal of medicinal chemistry
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Limited human research
  • •NNMT inhibition effects under investigation
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get 5-Amino-1MQ, baseline labs & clinician oversight.

Full 5-Amino-1MQ $/mg comparison →
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy 5-Amino-1MQ: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Bulletproof BioLabs — $1.80/mg (50mg vial, $90.00)
  2. 2. Elite Research USA — $2.00/mg (50mg vial, $100.00)
  3. 3. Limitless Peptides — $2.40/mg (50mg vial, $120.00)

Where is the cheapest place to buy 5-Amino-1MQ?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Bulletproof BioLabs at $1.80/mg (50mg vial, $90.00). We compared 5 US suppliers with live, checked prices.

How much does 5-Amino-1MQ cost per mg?

Verified US domestic prices currently range from $1.80/mg to $7.50/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is 5-Amino-1MQ approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.